ACP-103, a 5-HT2A receptor inverse agonist: Safety, tolerability, and pharmacokinetics in healthy volunteers

被引：0
|
作者：
Vanover, KE
Weiner, DM
Schlienger, N
Thygesen, M
Tolf, B
Hacksell, U
Brann, MR
Davis, RE
机构：
来源：
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY | 2004年 / 7卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：S253 / S253
页数：1
相关论文
共 50 条
  • [41] The safety, tolerability and pharmacokinetics of intravenous and oral LY334370, a selective 5HT1F receptor agonist (SSOFRA), in healthy subjects.
    Gossen, D
    de Suray, JM
    Vandenhende, F
    Demolle, D
    Onkelinx, C
    CEPHALALGIA, 1999, 19 (04) : 406 - 407
  • [42] Serotonin 5-HT2A receptor gene polymorphism, 5-HT2A receptor function and personality traits in healthy subjects:: a negative study
    Kusumi, I
    Suzuki, K
    Sasaki, Y
    Kameda, K
    Sasaki, T
    Koyama, T
    JOURNAL OF AFFECTIVE DISORDERS, 2002, 68 (2-3) : 235 - 241
  • [43] The Effects of the Preferential 5-HT2A Agonist Psilocybin on Prepulse Inhibition of Startle in Healthy Human Volunteers Depend on Interstimulus Interval
    Franz X Vollenweider
    Philipp A Csomor
    Bernhard Knappe
    Mark A Geyer
    Boris B Quednow
    Neuropsychopharmacology, 2007, 32 : 1876 - 1887
  • [44] Radiosynthesis and evaluation of the 5-HT2A inverse agonist: [11C]pimavanserin
    Andersen, Valdemar L.
    Hansen, Hanne
    Herth, Matthias
    Dyssegaard, Agnete
    Knudsen, Gitte Moos
    Kristensen, Jesper L.
    JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS, 2015, 58 : S330 - S330
  • [45] Safety, tolerability, pharmacokinetics, and pharmacodynamics of a TLR7 agonist prodrug RO6870868 in healthy volunteers
    Grippo, Joseph F.
    Folitar, Ilia
    Passe, Sharon
    Jiang, Qiudi
    Rodriguez, Ignacio
    Fettner, Scott H.
    Calleja, Elizabeth
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2021, 14 (04): : 1524 - 1534
  • [46] The effects of the preferential 5-HT2A agonist psilocybin on prepulse inhibition of startle in healthy human volunteers depend on interstimulus interval
    Vollenweider, Franz X.
    Csomor, Philipp A.
    Knappe, Bernhard
    Geyer, Mark A.
    Quednow, Boris B.
    NEUROPSYCHOPHARMACOLOGY, 2007, 32 (09) : 1876 - 1887
  • [47] Assessment of the pharmacokinetics, safety and tolerability of maraviroc, a novel CCR5 antagonist, in healthy volunteers
    Abel, Samantha
    van der Ryst, Elna
    Rosario, Maria C.
    Ridgway, Caroline E.
    Medhurst, Christine G.
    Taylor-Worth, Richard J.
    Muirhead, Gary J.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2008, 65 : 5 - 18
  • [48] Pharmacokinetics of a selective GABA-A alpha 5 receptor inverse agonistin healthy volunteers
    Xu, Y
    Merschman, S
    Petty, KJ
    Mazenko, RS
    Vega, JM
    Musson, DG
    NEUROBIOLOGY OF AGING, 2004, 25 : S198 - S198
  • [49] Single and Multiple Dose Safety, Tolerability and Pharmacokinetics of the Selective M1 Receptor Partial Agonist HTL0018318 in Healthy Volunteers
    Nathan, Pradeep
    Liptrot, Jan
    Bakker, Charlotte
    'tHart, Ellen
    Klaassen, Erica
    Prins, Samantha
    van der Doef, Thalia
    Walker, Mike
    Brown, Giles
    Brown, Alastair
    Congreve, Miles
    Weir, Malcolm
    Marshall, Fiona
    Cross, David
    Groeneveld, Geert Jan
    Tasker, Tim
    NEUROPSYCHOPHARMACOLOGY, 2018, 43 : S408 - S409
  • [50] Sustained treatment with a 5-HT2A receptor agonist causes functional desensitization and reductions in agonist-labeled 5-HT2A receptors despite increases in receptor protein levels in rats
    Shi, Ju
    Landry, Michelle
    Carrasco, Gonzalo A.
    Battaglia, George
    Muma, Nancy A.
    NEUROPHARMACOLOGY, 2008, 55 (05) : 687 - 692
12345